Surveillance of patients at risk of liver cancer: Expert opinions.

Liver cancer surveillance faces limited support due to lack of randomized trial evidence, with false positives and low sensitivity impacting effectiveness.

• Why it matters: Effective screening is crucial for early detection and improved survival, but current methods are hindered by weak evidence, especially outside hepatology, risking inefficient resource use.
• What they did: Experts reviewed existing observational data, risk prediction models, and ongoing research to evaluate current practices and potential improvements in liver cancer screening strategies.
• The result: Enhanced risk-based surveillance tailored to individual profiles could improve outcomes, but stronger evidence and policy advocacy are needed to optimize liver cancer detection and management.